deaths (OS)

metastatic/advanced - colorectal cancer (mCRC) metastatic/advanced - colorectal cancer (mCRC)

versus Standard of Care (SoC)
atezolizumab plus cometinib vs. Standard of Care (SoC) 1 certainty unassessable+35%

mCRC - 1st line (L1) metastatic/advanced - colorectal cancer (mCRC) mCRC - 1st line (L1)

mCRC - 2nd line (L2) metastatic/advanced - colorectal cancer (mCRC) mCRC - 2nd line (L2)

versus regorafenib
atezolizumab plus cometinib vs. regorafenib 1 certainty unassessable0%